Premium
Enalaprilat in Hypertensive Emergencies
Author(s) -
Strauss Ruth,
Gavras Irene,
Vlahakos Demetrios,
Gavras Haralambos
Publication year - 1986
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1986.tb02900.x
Subject(s) - enalaprilat , enalapril , medicine , furosemide , blood pressure , ace inhibitor , enalapril maleate , asymptomatic , angiotensin converting enzyme , adverse effect , anesthesia , pharmacology
Enalaprilat (MK‐422), an intravenously administered angiotensin‐converting enzyme inhibitor, which is the parent compound of the oral angiotensin‐converting enzyme inhibitor enalapril (MK‐421), was studied in 11 patients with asymptomatic accelerated hypertension. Each patient received an initial intravenous dose of 1 mg, followed at one‐hour intervals by enalaprilat 10 mg, furosemide 40 mg, and enalaprilat 40 mg. Six of 11 patients responded with a drop in mean arterial pressure > 15 mm Hg to diastolic levels below 110 mm Hg; there were four partial responders and one nonresponder. Pretreatment renins were not predictive of blood pressure response. No patient had any adverse reaction to the drug; there were no significant changes in posttreatment laboratory values. We conclude that enalaprilat is an effective, well‐tolerated agent for the treatment of uncomplicated accelerated hypertension and its use does not imperil nonresponding uncomplicated patients.